These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 1365563)

  • 1. [Renal clearance of rufloxacin in the healthy volunteer].
    Segre G; Cerretani D; Moltoni L; Urso R
    G Ital Chemioter; 1991; 38(1-3):123-6. PubMed ID: 1365563
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.
    Triger DR; Granai F; Woodcock J; Wise R; Imbimbo BP
    Hepatology; 1993 Oct; 18(4):847-52. PubMed ID: 8406358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rufloxacin, a new fluoroquinolone in biological fluids by high-performance liquid chromatography.
    Carlucci G; Fanini D; Pantaleoni GC; Palumbo G
    Acta Physiol Hung; 1990; 75 Suppl():49-50. PubMed ID: 2371900
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of rufloxacin in healthy volunteers.
    Segre G; Cerretani D; Moltoni L; Urso R
    Eur J Clin Pharmacol; 1992; 42(1):101-5. PubMed ID: 1311685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary excretion of rufloxacin in humans.
    Privitera G; Nicastro G; Imbimbo BP; Cesana M; Visconti M; Lombardi F; Tagliabue G; Faleschini E; Colturani F; Franzini P
    Antimicrob Agents Chemother; 1993 Dec; 37(12):2545-9. PubMed ID: 8109915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of rufloxacin in patients with impaired renal function.
    Perry G; Mant TG; Morrison PJ; Sacks S; Woodcook J; Wise R; Imbimbo BP
    Antimicrob Agents Chemother; 1993 Apr; 37(4):637-41. PubMed ID: 8388194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temafloxacin: the pharmacokinetic profile of a new quinolone. A seminar-in-print.
    Clin Pharmacokinet; 1992; 22 Suppl 1():1-107. PubMed ID: 1319864
    [No Abstract]   [Full Text] [Related]  

  • 8. Breakpoint determination: rufloxacin.
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):574-5. PubMed ID: 8404928
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics of enrofloxacin after single intravenous and intramuscular administration in young domestic ostrich (Struthio camelus).
    de Lucas JJ; Rodríguez C; Waxman S; González F; de Vicente ML; San Andrés MI
    J Vet Pharmacol Ther; 2004 Apr; 27(2):119-22. PubMed ID: 15096111
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of rufloxacin and norfloxacin effects on faecal flora.
    Marco F; Giménez MJ; Jiménez de Anta MT; Marcos MA; Salvá P; Aguilar L
    J Antimicrob Chemother; 1995 Jun; 35(6):895-901. PubMed ID: 7559202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The penetration of rufloxacin into sites of potential infection in the respiratory tract.
    Wise R; Andrews J; Imbimbo BP; Greaves I; Honeybourne D
    J Antimicrob Chemother; 1993 Dec; 32(6):861-6. PubMed ID: 8144426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.
    Kisicki JC; Griess RS; Ott CL; Cohen GM; McCormack RJ; Troetel WM; Imbimbo BP
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1296-301. PubMed ID: 1329618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.
    Vree TB; van den Biggelaar-Martea M; Imbimbo BP
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):45-9. PubMed ID: 1323466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
    Ito T; Yano I; Tanaka K; Inui KI
    J Pharmacol Exp Ther; 1997 Aug; 282(2):955-60. PubMed ID: 9262363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-performance liquid chromatographic determination of rufloxacin and its main active metabolite in biological fluids.
    Lombardi F; Ardemagni R; Colzani V; Visconti M
    J Chromatogr; 1992 Apr; 576(1):129-34. PubMed ID: 1323570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration.
    Cesana M; Broccali G; Imbimbo BP; Crema A
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):133-8. PubMed ID: 2071262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.
    Segre G; Cerretani D; Cerri D; Moltoni L
    Drugs Exp Clin Res; 1988; 14(12):747-54. PubMed ID: 3253051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue distribution and disposition kinetics of enrofloxacin in healthy and E. coli infected broilers.
    Soliman GA
    Dtsch Tierarztl Wochenschr; 2000 Jan; 107(1):23-7. PubMed ID: 10689795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis.
    Cox SK
    J Vet Pharmacol Ther; 2007 Oct; 30(5):381-6. PubMed ID: 17803728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs.
    Anadón A; Martínez-Larrañaga MR; Díaz MJ; Fernández-Cruz ML; Martínez MA; Frejo MT; Martínez M; Iturbe J; Tafur M
    Am J Vet Res; 1999 Nov; 60(11):1377-82. PubMed ID: 10566812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.